Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Bristol-Myers Stock Jumps On Takeover Speculation

By Pharmaceutical Processing | February 3, 2009

NEW YORK (AP) — Shares of Bristol-Myers Squibb Co. jumped Monday amid speculation it could become an acquisition target. Talk of another round of industry consolidation was stirred up by news last Monday that top-selling drugmaker Pfizer Inc. plans to buy Wyeth for $68 billion. Speculation heated up further after the new CEO of Sanofi-Aventis SA, the world’s No. 4 drugmaker, reportedly told employees of the French company that it’s considering acquisitions. Shares of Bristol-Myers — often seen as an acquisition target and specifically mentioned as a possible Sanofi target in a news report Sunday — rose 2.7 percent to close at $21.99 Monday. Earlier in the session, the stock traded as high as $22.79. “It’s speculation that they might be an attractive takeover target. Today’s speculation is Sanofi” as the acquirer, said Deutsche Bank analyst Barbara Ryan. London’s Financial Times reported Sanofi “has held talks with bankers about possible deals,” and could raise more than $20 billion, according to one analyst’s estimate. Bristol-Myers and Sanofi already have a relationship, splitting revenue from blood thinner Plavix, the world’s second-best-selling drug. Chris Viehbacher just became chief executive at Sanofi in December, after having been head of British rival GlaxoSmithKline’s U.S. and then North American pharmaceuticals division. Experts speculate Viehbacher wants to make a mark with a big move. Meanwhile, Ryan thinks part of the jump in Bristol’s shares is related to a Food and Drug Association advisory panel hearing Tuesday on an experimental blood thinner from Eli Lilly & Co. that would compete with Plavix if approved. A lengthy report by FDA reviewers released last Friday indicates they see Lilly’s drug, prasugrel, as being more effective than Plavix but with a higher risk of life-threatening bleeding. Ryan said she thinks that will limit the use of prasugrel. “It doesn’t look like it would have the ammo to derail Plavix” sales, she said.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE